Marie Titecat1, Xiaofei Liang2, Chul-Jin Lee3, Audrey Charlet1, Didier Hocquet4, Thierry Lambert5, Jean-Marie Pagès6, René Courcol1, Florent Sebbane1, Eric J Toone7, Pei Zhou7, Nadine Lemaitre8. 1. Univ. Lille, CNRS, INSERM, CHU Lille, U1019-UMR 8204, Center for Infection and Immunity of Lille, F-59000 Lille, France. 2. Department of Chemistry, Duke University, Durham, NC 27708, USA. 3. Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA. 4. UMR CNRS 6249, Chrono-environnement, Université de Bourgogne-Franche-Comté, Centre de Ressources Biologiques Ferdinand Cabanne, Hygiène Hospitalière, CHU Besançon, F-25000 Besançon, France. 5. EA 4043 Unité Bactéries Pathogènes et Santé (UBaPS), Univ. Paris-Sud, Unité Paris Saclay, F-92290 Châtenay-Malabry, France. 6. UMR-MD1, Aix Marseille Université, Institut de Recherche Biomédicale des Armées, F-13000 Marseille, France. 7. Department of Chemistry, Duke University, Durham, NC 27708, USA Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA. 8. Univ. Lille, CNRS, INSERM, CHU Lille, U1019-UMR 8204, Center for Infection and Immunity of Lille, F-59000 Lille, France nadine.lemaitre@chru-lille.fr.
Abstract
OBJECTIVES: Inhibitors of uridine diphosphate-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC, which catalyses the first, irreversible step in lipid A biosynthesis) are a promising new class of antibiotics against Gram-negative bacteria. The objectives of the present study were to: (i) compare the antibiotic activities of three LpxC inhibitors (LPC-058, LPC-011 and LPC-087) and the reference inhibitor CHIR-090 against Gram-negative bacilli (including MDR and XDR isolates); and (ii) investigate the effect of combining these inhibitors with conventional antibiotics. METHODS: MICs were determined for 369 clinical isolates (234 Enterobacteriaceae and 135 non-fermentative Gram-negative bacilli). Time-kill assays with LPC-058 were performed on four MDR/XDR strains, including Escherichia coli producing CTX-M-15 ESBL and Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii producing KPC-2, VIM-1 and OXA-23 carbapenemases, respectively. RESULTS: LPC-058 was the most potent antibiotic and displayed the broadest spectrum of antimicrobial activity, with MIC90 values for Enterobacteriaceae, P. aeruginosa, Burkholderia cepacia and A. baumannii of 0.12, 0.5, 1 and 1 mg/L, respectively. LPC-058 was bactericidal at 1× or 2× MIC against CTX-M-15, KPC-2 and VIM-1 carbapenemase-producing strains and bacteriostatic at ≤4× MIC against OXA-23 carbapenemase-producing A. baumannii. Combinations of LPC-058 with β-lactams, amikacin and ciprofloxacin were synergistic against these strains, albeit in a species-dependent manner. LPC-058's high efficacy was attributed to the presence of the difluoromethyl-allo-threonyl head group and a linear biphenyl-diacetylene tail group. CONCLUSIONS: These in vitro data highlight the therapeutic potential of the new LpxC inhibitor LPC-058 against MDR/XDR strains and set the stage for subsequent in vivo studies.
OBJECTIVES: Inhibitors of uridine diphosphate-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC, which catalyses the first, irreversible step in lipid A biosynthesis) are a promising new class of antibiotics against Gram-negative bacteria. The objectives of the present study were to: (i) compare the antibiotic activities of three LpxC inhibitors (LPC-058, LPC-011 and LPC-087) and the reference inhibitor CHIR-090 against Gram-negative bacilli (including MDR and XDR isolates); and (ii) investigate the effect of combining these inhibitors with conventional antibiotics. METHODS: MICs were determined for 369 clinical isolates (234 Enterobacteriaceae and 135 non-fermentative Gram-negative bacilli). Time-kill assays with LPC-058 were performed on four MDR/XDR strains, including Escherichia coli producing CTX-M-15 ESBL and Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii producing KPC-2, VIM-1 and OXA-23 carbapenemases, respectively. RESULTS:LPC-058 was the most potent antibiotic and displayed the broadest spectrum of antimicrobial activity, with MIC90 values for Enterobacteriaceae, P. aeruginosa, Burkholderia cepacia and A. baumannii of 0.12, 0.5, 1 and 1 mg/L, respectively. LPC-058 was bactericidal at 1× or 2× MIC against CTX-M-15, KPC-2 and VIM-1 carbapenemase-producing strains and bacteriostatic at ≤4× MIC against OXA-23 carbapenemase-producing A. baumannii. Combinations of LPC-058 with β-lactams, amikacin and ciprofloxacin were synergistic against these strains, albeit in a species-dependent manner. LPC-058's high efficacy was attributed to the presence of the difluoromethyl-allo-threonyl head group and a linear biphenyl-diacetylene tail group. CONCLUSIONS: These in vitro data highlight the therapeutic potential of the new LpxC inhibitor LPC-058 against MDR/XDR strains and set the stage for subsequent in vivo studies.
Authors: H R Onishi; B A Pelak; L S Gerckens; L L Silver; F M Kahan; M H Chen; A A Patchett; S M Galloway; S A Hyland; M S Anderson; C R Raetz Journal: Science Date: 1996-11-08 Impact factor: 47.728
Authors: Chul-Jin Lee; Xiaofei Liang; Xin Chen; Daina Zeng; Sang Hoon Joo; Hak Suk Chung; Adam W Barb; Shauna M Swanson; Robert A Nicholas; Yaoxian Li; Eric J Toone; Christian R H Raetz; Pei Zhou Journal: Chem Biol Date: 2010-12-16
Authors: Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen Journal: Chem Rev Date: 2018-09-07 Impact factor: 60.622
Authors: Jason Munguia; Doris L LaRock; Hannah Tsunemoto; Joshua Olson; Ingrid Cornax; Joseph Pogliano; Victor Nizet Journal: J Mol Med (Berl) Date: 2017-08-26 Impact factor: 4.599
Authors: Christopher S Henry; Ella Rotman; Wyndham W Lathem; Keith E J Tyo; Alan R Hauser; Mark J Mandel Journal: J Infect Dis Date: 2017-02-15 Impact factor: 5.226
Authors: Mina Mostafavi; Lisha Wang; Lili Xie; Kenneth T Takeoka; Daryl L Richie; Fergal Casey; Alexey Ruzin; William S Sawyer; Christopher M Rath; Jun-Rong Wei; Charles R Dean Journal: mSphere Date: 2018-10-31 Impact factor: 4.389